Mark Bradley

www.transmed7.com We create minimally invasive medical technology addressing patient needs from diagnosis to therapy. TransMed7 is a privately-held medical technology company founded in 2010 to rapidly generate new minimally invasive medical devices for diverse fields of healthcare around the world. Our Clinical and Scientific Advisory Board, together with our global network of internationally recognized clinician leaders, precisely guide TransMed7’s technology development in near-real time. We maintain collaborative partnerships with providers of adjunct technologies that ensure our innovation leadership far into the future. Medical technology concepts that we generate and protect from an intellectual property (IP) perspective are placed into our technology pipeline. From there, TransMed7’s leadership team critically assesses each concept’s viability as well as potential capabilities to accelerate adoption. A technology concept must meet our stringent criteria in order to undergo full product development, including the ability to quickly expand a powerful intellectual property. Technology concepts that meet our criteria for product development are generally organized as stand-alone subsidiary project companies. A Project LLC schedule begins with technology concept refinement, proceeds through product development, and ends with US/OUS market release. The process of multiple TransMed7 Project LLCs operating simultaneously provides economies of scale, leveraging our highly experienced pool of scientists, engineers, and quality assurance/regulatory personnel to lead best-practices, quality-compliant product development. In some cases, we may choose to work closely with one or more Strategic Partners who are committed to acquiring our medical technologies and bringing them to the healthcare market rapidly. In these cases, the Project LLC is developed to an optimal level that maximizes valuation for acquisition and exit placement with a chosen Strategic Partner.

RefundIQ is revolutionizing consumer financial recovery through fully automated AI-powered refund identification, communication generation, sending, and escalation management. Founded in 2024, RefundIQ combines advanced email scanning technology with credit card integration to completely automate the post-refund process. Our AI writes, sends, and tracks professional communications with merchants, escalating to credit card disputes when businesses fail to pay refunds owed. Mission Statement "To completely automate consumer financial recovery - our AI finds, tracks, communicates, and escalates every refund opportunity, so you never leave money on the table."

www.transmed7.com We create minimally invasive medical technology addressing patient needs from diagnosis to therapy. TransMed7 is a privately-held medical technology company founded in 2010 to rapidly generate new minimally invasive medical devices for diverse fields of healthcare around the world. Our Clinical and Scientific Advisory Board, together with our global network of internationally recognized clinician leaders, precisely guide TransMed7’s technology development in near-real time. We maintain collaborative partnerships with providers of adjunct technologies that ensure our innovation leadership far into the future. Medical technology concepts that we generate and protect from an intellectual property (IP) perspective are placed into our technology pipeline. From there, TransMed7’s leadership team critically assesses each concept’s viability as well as potential capabilities to accelerate adoption. A technology concept must meet our stringent criteria in order to undergo full product development, including the ability to quickly expand a powerful intellectual property. Technology concepts that meet our criteria for product development are generally organized as stand-alone subsidiary project companies. A Project LLC schedule begins with technology concept refinement, proceeds through product development, and ends with US/OUS market release. The process of multiple TransMed7 Project LLCs operating simultaneously provides economies of scale, leveraging our highly experienced pool of scientists, engineers, and quality assurance/regulatory personnel to lead best-practices, quality-compliant product development. In some cases, we may choose to work closely with one or more Strategic Partners who are committed to acquiring our medical technologies and bringing them to the healthcare market rapidly. In these cases, the Project LLC is developed to an optimal level that maximizes valuation for acquisition and exit placement with a chosen Strategic Partner.

The Lyle School of Engineering at SMU in Dallas, Texas, has been shaping world-changing engineers for nearly 100 years. We are devoted to helping cultivate bold engineers who discover, lead and create new economic opportunities while meeting the most difficult challenges facing society. SMU Lyles faculty is recognized internationally for their remarkable contributions to engineering and society across five academic departments.